
    
      OBJECTIVES:

        -  Determine the antitumor activity of epirubicin and thalidomide in patients with locally
           unresectable or metastatic hepatocellular carcinoma.

        -  Determine the toxic effects of this regimen in these patients.

      OUTLINE: Patients receive epirubicin on days 1, 8, and 15 and thalidomide on days 1-21.
      Courses repeat every 28 days.

      PROJECTED ACCRUAL: A total of 12 patients per year will be accrued for this study.
    
  